Cancer Precision Diagnostics Articles & Analysis
114 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. ...
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...
Today about 20 cancer treatments approved by FDA and EMA are directed towards specific gene fusions, and the number of drugs available is growing annually. The increased importance of gene fusions in oncology is driving demand from diagnostic laboratories for scalable analytical solutions. RNA can be used to analyze gene fusions. Moreover, while DNA is largely identical in all cells, RNA ...
While DNA is largely identical in all cells, RNA fluctuates considerably both in presence and relative concentrations. The variation reflects the underlying cause of a cell’s character and thus RNA analysis gives a more accurate view of the state cells are in compared to DNA analysis. Gene expression levels are important to analyse, and quantitative RNA sequencing is the most informative ...
Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms vision for improving cancer patients’ diagnostics. This is achieved by developing and providing integrated and standardized workflows for Next Generation Sequencing (NGS) and integrating information from cancer gene testing, pharmacogenetics testing and e-medication, to ...
Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) issued in relation to ...
Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) ...
We are enthusiastic to share the results of the research conducted by Dr Tamminga from the University of Groningen. ISET Technology applied to DLA products. This research opens a new interesting way to look at the very rare cancer cells in the patient bloodstream. Rarecells Diagnostics (France), a leading liquid biopsy company, is pleased to announce that the University Medical Center of ...
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. The funds will support the start of laboratory and clinical operations in the United-States focused on Prostate Cancer and Acute Myeloid Leukemia early detection tests. Rarecells ...
Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC). The ...
Meet us from October 12 – 13, 2022 at the Diagnostics-4-Future conference in Konstanz and learn more about our know-how in the fields of contract manufacturing, contract development, lifecycle management and many more. Meet LRE Medical at booth #16 or if you would like to set an appointment, please reach out to Claudia Strehle at strehle@lre.de. Diagnostics-4-Future is an ...
Vancouver, British Columbia – (September 20, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that the US Patent Office (USPTO) has granted BioMark patent number US 11,447,168 that covers a novel approach to diagnosing ...
Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival? SAGA Diagnostics AB is seeking a talented and highly motivated Bioinformatics Scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through proprietary ultrasensitive technologies that measure circulating tumor DNA (ctDNA) in ...
INOVIQ (ASX:IIQ) is developing and commercialising next-generation exosome capture tools and precision diagnostics in what CEO Dr Leearne Hinch says is a $15bn medical diagnostics market opportunity for some of the most common – and deadly - cancers. “There’s a clear unmet need for earlier and more accurate ...
Vancouver, British Columbia – (September 8, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it’s abstract titled “Metabolomic Profiling for the Early Detection of Lung Cancer” has been ...
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more cancer patients with access to SEngine’s signature diagnostic test, the PARIS® Test. This collaboration, ...
X-ZELL is proud to announce the appointment of Michael Tillmann as member of the company’s executive board. Drawing on more than 30 years of experience in the pharmaceutical and diagnostics industry, Mr Tillmann previously held the CEO position at Roche Diagnostics North America and Asia Pacific. Between 2006 and 2010, he also served as a member of the company’s global executive ...
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). On September 1, New York, New Jersey, Chicago, and Puerto Rico will simultaneously light up dozens of landmarks and ...
Bot Image : Bot Image is a medical device company that created a product for post-processing MRI that is using artificial intelligence (AI) to aid physicians in image interpretation by providing highly accurate prostate cancer diagnostics. The software is provided as a SaaS model or can be installed behind the client’s firewall. ...